The chimeric oncogene Bcr-Abl is known to induce autonomous motility of leukemic cells. We show here that p210 
Introduction
Bcr-Abl is a chimeric oncogene generated by a reciprocal translocation between chromosomes 9 and 22 (Philadelphia chromosome, Ph þ ) that leads to the fusion of the 5 0 region of the bcr gene with the 3 0 region of the abl gene. This translocation is found in most patients with chronic myelogenous leukemia (CML) and a fraction of those with acute lymphoblastic leukemia (ALL) (Sawyers, 1999; Deininger et al., 2000) . Bcr is a multidomain cytoplasmic protein composed of an oligomerization N-terminal domain, a serine kinase domain, a DH/PH domain (Dbl-Homology/Pleckstrinhomology) specific for RhoA and a C-terminal GTPase activating protein domain that inactivates Rac. Abl is a nonreceptor tyrosine kinase, which regulates among others actin reorganization, and is an important component in hematopoietic cells (Van Etten, 1999; Hernandez et al., 2004) .
Depending on the breakpoint region of the bcr gene implicated in the translocation, various Bcr-Abl chimeras are observed. The most frequent one is p210 bcr-abl , which is responsible for CML (Daley et al., 1990) , while p190 bcr-abl is responsible for ALL (Clark et al., 1988) . Both proteins exhibit enhanced and constitutive tyrosine kinase activity, which is the central mechanism of leukemogenesis (Lugo et al., 1990; Ilaria and Van Etten, 1996) .
The only structural difference between these two proteins is the presence of the GDP/GTP exchange factor (GEF) domain of Bcr ( Figure 1A ) in p210 bcr-abl . The isolated recombinant DH domain of Bcr is an activator of Rho GTPases (Chuang et al., 1995) . We previously reported that p210
bcr-abl could be a GEF only for RhoA. We also identified p95 vav as a partner of both forms of Bcr-Abl that could be responsible for Rac1 activation (Harnois et al., 2003) . A hypothetical model of Bcr-Abl-induced leukemogenesis involving Rho GTPases could be argued. In this model, the common activation of Rac1 and Cdc42 by p190
bcr-abl and p210
bcr-abl could participate in the aggressivity of Bcr-Abl-associated leukemia, by enhancing cell motility and proliferation, and by inhibiting apoptosis. In contrast, RhoA activation, specific of p210
bcr-abl -expressing cells, could be responsible for the chronic phenotype associated with this latter chimera. Some of the RhoAinduced pathways as hematopoietic differentiation should be important in this perspective (Nakashima and Nozawa, 1999) .
The Vav protein family possesses three known members in mammalian cells: Vav, Vav2 and Vav3. The proto-oncogene p95
vav is predominantly expressed in hematopoietic cells (Bustelo, 2000) . Vav is activated by tyrosine phosphorylation (Crespo et al., 1997) and is a substrate of Bcr-Abl (Matsuguchi et al., 1995) . Moreover, Vav is found in complex with p210 bcr-abl through its C-terminal SH2 domain (Bassermann et al., 2002) . Vav has been shown to be an exchange factor essentially for Rac1 (Crespo et al., 1997) and our previous results showed that Vav1 is not a GEF for RhoA (Harnois et al., 2003) .
Rho family proteins are key regulators of cell motility. Their role has been particularly studied in mesenchymal cells (Raftopoulou and Hall, 2004) . In contrast, the molecular mechanisms associated with the motility of haematopoietic cells, which are the most rapid cells, remain to be detailed. In this context, the differential activation of Rho GTPases by p190
bcr-abl should represent a useful cellular model. A characteristic of leukemic cells is to migrate outside from the haematopoietic compartment in immature states. The aim of this work was to study the Bcr-Abl-induced motility of leukemic cells and to address the role of GEF activities linked to p190 bcr-abl or p210 bcr-abl in this action. Here we show that the Rac1 activation by Vav induced by Bcr-Abl leads to triggering of the motility of leukemic cells, and that the specific activation of RhoA by the DH/PH domain of p210 bcr-abl modifies the mode of motility, which is basically a rolling type to an amoeboid type.
Results
Differential motility of Bcr-Abl-expressing Ba/F3 cells We previously observed by confocal microscopy (Harnois et al., 2003) that Ba/F3p190 were spherical cells, while Ba/F3p210 cells showed stretched body with heterogeneous shapes. To question if these differential shapes corresponded to different modes of motility, we performed time-lapse recordings of cell movements in 3D matrigel or collagen. The only morphological change between wild-type Ba/F3 and empty vectorexpressing cells (Ba/F3pGD) was a slight volume increase. Both cell types presented no cellular movements and remained spherical, smooth and immobile during the recording time (Figure 1Ba,b) . Ba/F3p190 cells remained strictly spherical during recording, while Ba/F3p210 cells showed characteristic amoeboid movements (Figure 1Bc,d) . Ba/F3p190 cells were highly mobile cells using a rolling-type motility, crawling into 3D matrigel with the help of pseudopodia. In contrast, Ba/F3p210 cells showed spontaneous cell motility by amoeboid movements. During 10 min recording, we observed that 53% of Ba/F3p210 cells displayed amoeboid cell motility (Table 1) . However longer observations indicated that all Ba/F3p210 cells were able to be spontaneously mobile but not synchronously. All cells cycled between resting periods in which the cell body was either spherical or irregular, and mobile periods with changes in cell body shape characteristic of amoeboid movements.
In transwell experiments through 3D matrigel, wildtype Ba/F3 and Ba/F3pGD cells presented no spontaneous motility. In contrast, Ba/F3p190 and Ba/F3p210 cells spontaneously colonized and moved into 3D matrigel. The migration rate of Ba/F3p190 cells was significantly higher than Ba/F3p210 cells ( Figure 1C ).
ShRNA inhibition of Vav expression leads to cell immobilization
We previously showed that Rac1 was activated in both Ba/F3p190 and Ba/F3p210 cells, while RhoA was found in an activated state only in Ba/F3p210 cells (Harnois et al., 2003) . We also demonstrated the presence of active p95
vav in Bcr-Abl complexes. In order to understand the role of Vav in Bcr-Abl-induced cell motility, we transfected shRNAs to deplete Vav in Ba/F3pGD, Ba/F3p190 and Ba/F3p210 cells. An 85% inhibition of Vav expression was obtained using shRNA1 as assessed by fluorescence-activated cell sorting (FACS) analysis (data not shown) or western blot analysis (Figure 2a ). The amount of activated Rac1 was significantly lowered in shRNA1-transfected cells in comparison with control-shRNA-or shRNA2-transfected cells, except in Ba/F3pGD in which it remained constantly low ( Figure 2a) . Transwell analysis of cell migration through 3D matrigel indicated that control-shRNA or shRNA2 induced no modification of cell motility. In contrast, transfection of shRNA1 led to a dramatic inhibition of Ba/F3p190 and Ba/F3p210 cell motility, while Ba/F3pGD cells remained immobile (Figure 2b) . 
Time-lapse recordings were analysed using three criteria: (1) (Harnois et al., 2003) . Previous reports used deletion mutants of Vav, containing only its C-terminal SH3 and SH2 domains (Bassermann et al., 2002) . These constructs act as dominant-negative mutants of Vav for all of its activities. As well as Vav knockdown, they did not address the specific question of GEF activity. We then constructed a point mutant in the DH domain (VavT205A) similar to the one described for Dbl and SoS (Zheng et al., 1997) (Figure 3a Figure 3b and Supplementary data, Figure 1 ).
Selection of Ba/F3p210S509A cells was performed as previously described (Daley and Baltimore, 1988) , independence toward interleukin-3 (IL-3) was obtained after 1 week of culture. Western blot of anti-Abl immunoprecipitation in Ba/F3p190, Ba/F3p210 and Ba/F3p210S509A cells revealed by anti-Abl antibody showed that the expression levels of p190 (3) p210 bcr-abl is the unique vector of RhoA activation in Ba/F3p210 cells.
Vav and Bcr-Abl modulate the motility of Ba/F3 cells The role of Rho GTPases in cell motility has been well documented (Raftopoulou and Hall, 2004) . We analysed cell movements by time-lapse microscopy recording in 3D matrigel and studied the spontaneous migration of the cell lines through 3D matrigel using transwell experiments.
In Both Ba/F3p190 and Ba/F3p210 cells produced short and active pseudopodia, which could be qualified as ruffles, filopodia and occasionally lamellipodia. The production and the persistence of these pseudopodia were comparable between Ba/F3p190, Ba/F3p190Vav Ba/F3p210 and Ba/F3p210Vav cells (Table 1) . Expression of VavL in Ba/F3p190 or Ba/F3p210 cells led to similar results: enhancement of the persistence of pseudopodia, which were longer and larger, and a 50% inhibition of pseudopodia production (Table 1) . In contrast, VavT205A expression almost abolished the production of new pseudopodia, which were less persistent, short and diffuse along the membrane (Figures 5d and g amoeboid deformation was also observed in a minority of Ba/F3p210S509A cells (Table 1) . A rolling-type motility using pseudopodia without deformation of the cell body, similar to Ba/F3p190 cells was observed for more than 90% of Ba/F3p210S509A mobile cells.
The spontaneous motility of Ba/F3 cells was studied in transwell experiments through 3D matrigel. Expression of Vav had no effect on the invasion of Ba/F3p190 or Ba/F3p210 cells (Figure 6a ). In contrast, expression of VavL in Ba/F3p190 or in Ba/F3p210 cells induced a 4-to 4.5-fold enhancement of cell motility, while in wildtype Ba/F3 cells no significant enhancement of motility was observed. Conversely, expression of VavT205A in Ba/F3p190 or in Ba/F3p210 cells inhibited cell motility to a level nearly comparable to wild-type Ba/F3 or Ba/F3pGD cells. Ba/F3p210S509A cells presented a 2.5-fold enhancement of migration rate in comparison with Ba/F3p210 cells (Figure 6a ).
Amoeboid movements are the consequence of p210 bcr-abl -induced RhoA activation C3 exoenzyme from Clostridium botulinum is an adenosine diphosphate-ribosyl transferase that specifically inhibits RhoA, although it is active on RhoB and RhoC as well. To address the role of RhoA in cell motility, we treated Ba/F3 strains with C3 for 6 h.
In transwell experiments through 3D matrigel, C3 exoenzyme treatment induced no modification in the motility of Ba/F3p190 cells, co-expressing or not Vav or Vav mutants. In contrast, an enhancement of spontaneous motility of Ba/F3p210 cells expressing or not Vav or Vav mutants was observed (Figure 6b ). It is noticeable that C3-treated Ba/F3p210 cells exhibited an enhancement of spontaneous motility to a level comparable to Ba/F3p210S509A cells. Interestingly, motility of Ba/F3p210S509A cells was not affected by C3 exoenzyme treatment.
In time-lapse recordings of cell movements, Ba/ F3p190 cells, co-expressing or not Vav or Vav mutants, exhibited no change after C3 treatment, even after 24 h (Figures 7c-f) . In contrast, Ba/F3p210, Ba/F3p210Vav, Ba/F3p210VavL and Ba/F3p210VavT205A cells were subjected to strong modifications (Figures 7g-j) ) were transfected with 2 mg of plasmids containing (1) a control shRNA sequence and (2) vavspecific shRNA sequences (shRNA1 and shRNA2) using a Nucleofector device (Amaxa). After 48 h of culture, cells were lysed as described in the 'Material and methods' section, and 20 mg of total protein was loaded on an 11% SDS-PAGE, western blotted and revealed using anti-Vav or anti-Rac1 antibodies (upper and lower panels). In parallel, pull-down assay was performed on 200 mg of protein using GST-PAK-CD as a bait for GTP-bound Rac1. Bead-bound proteins were loaded onto 13% SDS-PAGE, western blotted and revealed using anti-Rac1 antibody (middle panel). (b) Transwell measurement of shRNA-transfected cells. Results were obtained as in Figure 1C and are mean values ± s.d. (n ¼ 3).
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Discussion
Cell motility has been extensively studied for the last 15 years, but almost exclusively for the mesenchymal mode of motility and on 2D surfaces. Haematopoietic cells, which are the most rapid cells, move quite differently (Friedl and Wolf, 2003) . We show here that, as many other haematopoietic cells, Ba/F3p210 cells use an amoeboid mode of motility. In contrast, Ba/F3p190 cells, while highly motile, show no amoeboid motility and crawl by rolling. In a previous report, we have shown that the major difference between these chimeras resides in p210 bcr-abl ability to activate RhoA (Harnois et al., 2003) . While the macromolecular complexes 5 cells of each type were lysed in Lae¨mmli loading buffer and migrated in 9% SDS-PAGE and blotted onto nitrocellulose membrane. pHis-tagged proteins were visualized using anti-His antibody. In parallel, 1/10 of the lysates were loaded onto a 10% SDS-PAGE, blotted and revealed using anti-tubulin antibody to assess of the total protein loading. (c) Expression of Bcr-Abl chimera in Ba/F3 cells: 20 mg of Ba/ F3pGD, Ba/F3p190, Ba/F3p210 and Ba/F3p210S509A cell lysates were loaded onto an 8% SDS-PAGE and immunoblotted using antiAbl antibody. (d) Tyrosine-kinase activity of Bcr-Abl chimera expressed in Ba/F3 cells. A total of 2 Â 10 5 Ba/F3pGD, Ba/F3p190, Ba/ F3p210 and Ba/F3p210S509A cells were seeded in 24-well plate and incubated in RPMI 1640 complete medium containing or not 10 mM CGP-571 for 12 h. Cells were then lysed in lysis buffer containing 100 mM vanadate and 10 mg of total protein was loaded onto a 9% SDS-PAGE. The western blot was revealed using PY-20 antibody. (e) Presence of Vav in complex with each Bcr-Abl chimera. Ba/F3p190, Ba/ F3p210 and Ba/F3p210S509A cells were lysed as described in the 'Materials and methods' section. Lysates (200 mg) were incubated with anti-Vav (upper panel) or anti-Abl (lower panel) antibody and immunoprecipitation was performed as described in the 'Materials and methods' section. Lysates (10 mg) and immunoprecipitates migrated onto 8% SDS-PAGE were then blotted on nitrocellulose membrane. The presence of Bcr-Abl chimera or Vav were revealed using anti-Abl antibody (upper panel) or anti-Vav antibody (lower panel).
Differential Bcr-Abl-induced cell motility T Daubon et al organized around p190 bcr-abl or p210 bcr-abl presented a GEF activity toward Rac1 and Cdc42, the macromolecular complex organized around p210 bcr-abl was the only one able to activate RhoA. It has been shown that BcrAbl enhances the motility of leukemic cells, through actin cytoskeletal proteins phosphorylation and abnormal integrin function (Salgia et al., 1997; Bhatia et al., 1999). However, the role of Rho-GTPases and Bcr-Ablassociated GEF activities in these changes has never been explored. The tyrosine-kinase-independence of adhesion abnormalities induced by Bcr-Abl (Wertheim et al., 2002) , and the comparable tyrosine-kinase activities of p190 bcr-abl and p210 bcr-abl (Ilaria and Van Etten, 1996 ; Figure 2d ) suggest that differential cell Differential Bcr-Abl-induced cell motility T Daubon et al movements are not related to tyrosine-kinase activity. Our previously published data argued for a role of Vav in Bcr-Abl-associated complexes toward Rac1 and of the DH/PH domain of p210 bcr-abl toward RhoA although no data existed to attribute the GEF activity to one of the known components of the complex.
We first depleted the Bcr-Abl-expressing cells of Vav using shRNA. Interestingly, in addition to the loss of activated Rac1, already observed with dominant-negative Vav (Bassermann et al., 2002) , a dramatic decrease in spontaneous motility through 3D matrigel was obtained as assessed by transwell experiments (Figure 2b) . To address the respective role of Rho GTPases in the motility processes, we constructed and expressed negative mutants of the GEFs previously found associated with Bcr-Abl (Harnois et al., 2003) . The VavT205A mutant, different from previously used deletion mutants (Bassermann et al., 2002) , was designed to address the specific question of GEF activity. Interestingly, Vav-depleted Ba/F3p210 cells still presented amoeboid shape in time-lapse experiments (data not shown). From our in vitro experiments and cellular behavior observations, we can conclude that the T205A mutant is devoid of GEF activity toward Rac1. Indeed, in Ba/F3p210VavT205A and Ba/F3p190Vav-T205A cells only residual activated Rac1 was observed, Differential Bcr-Abl-induced cell motility T Daubon et al comparable to the level in wild-type Ba/F3 cells (Figure 4a ). In vitro GEF activity measurements of purified VavT205A showed no activity toward Rac1 (data not shown), while purified Vav from Ba/F3p190 or Ba/F3p210 cells presented a classical GEF activity toward Rac1 (Harnois et al., 2003) .
The present results clearly show that the DH/PH domain of p210 bcr-abl is uniquely responsible for RhoA activation in p210 bcr-abl -expressing cells, which in turn leads to amoeboid movements. Indeed, expression of the p210 bcr-abl S509A mutant totally abolished the presence of GTP-bound RhoA. We show here that the S509A mutation on p210 bcr-abl suppresses RhoA activation and amoeboid-type motility of Ba/F3 cells (Figures 4b and 5h) . Similarly, C3-exoenzyme treatment of p210 bcr-abl -expressing cells suppressed the presence of amoeboid movements (Figures 7g-j) . We can conclude that the DH domain of p210 bcr-abl is the unique vector of RhoA activation in this model, and that RhoA activation is responsible for the amoeboid mode of motility, as observed in several models (Yamazaki et al., 2005) .
Our results show that Vav is the major GEF responsible for Rac1 activation. Inhibition of the GEF activity of Vav and consequently inactivation of Rac1 induced the loss of membrane protrusion production and ruffles, but also abolished the motility of p190 of Bcr-Abl-expressing cells, but no modification of the mode of motility (that is, rolling for p190 bcr-abl versus amoeboid for p210 bcr-abl ). Noticeably, C3-exoenzyme treatment, which did not affected the spontaneous motility of p190 bcr-abl -expressing cells in transwell experiments, conversely enhanced p210 bcr-abl -expressing cell migration. C3 treatment was known to totally inhibit the spontaneous motility of bovine neutrophils (Stasia et al., 1991) . Thus, the presence of spontaneous motility in absence of RhoA activation could be a specificity of Bcr-Abl. We can then conclude that the GEF activity of Vav is indispensable for Bcr-Abl-induced motility, while RhoA activation by the DH domain of p210 bcr-abl do not trigger motility but promotes an amoeboid type. Activation of RhoA and thus the presence of amoeboid movements may slow down the spontaneous motility of Bcr-Abl-expressing cells. Recently, Rho pathway was identified as a target for Bcr-Abl, but inhibition of RhoA induced a decrease in SDF-1-stimulated motility (Unwin et al., 2005) . It should be noted that we studied the spontaneous motility of Bcr-Abl-expressing cells, and not the chemokine-induced motility.
Our data demonstrates a key role of Vav in cooperation with Bcr-Abl in the induction of leukemic cell motility. The Bcr-Abl-expressing cells also represent a useful model to study the role of Rho GTPases in the motility of nonmesenchymal cells which is actually poorly understood. The comprehension of the molecular mechanisms of cytoskeleton remodeling leading to amoeboid movements or to rolling would give new insights in the cell biology of motility. In this cellular model (Figure 8 ), the major activation of Vav and Rac1 by Bcr-Abl stimulates the migration of leukemic cells by a rolling type, which seems to be the basic mode of motility of Bcr-Abl-expressing cells. When the p210 bcr-abl chimera is expressed, the specific activation of RhoA by the DH/PH domain leads to the transition to an amoeboid mode of motility.
Future work on patient cells should help to explore the consequences for leukemic cells of the changes in motility mode and to determine if the p210 bcr-abl -induced amoeboid mode of motility is related to the chronic phenotype, while the rolling mode of motility is in relation with the more aggressive phenotype linked to p190 bcr-abl .
Materials and methods

Cell lines and cDNA constructs
Culture of Ba/F3 and Bcr-Abl-expressing cell lines Ba/F3p210 and Ba/F3p190 was described previously (Harnois et al., 2003) . The pGD210S509A vector was obtained by directed mutagenesis of pGD210 vector using the QuickChange kit (Stratagene, France) with specific primer. Ba/F3p210S509A cell line was obtained as described for Ba/F3p210 and Ba/ F3p190 cells (Daley and Baltimore, 1988) and grew in the absence of IL-3. A Ba/F3 cell line expressing the pGD empty vector (Ba/F3pGD) was obtained, and grew in the presence of G418 (0.7 mg ml
À1
) and rm-IL-3 (10 ng ml À1 ). Vav cDNA was cloned in the expression vector pEF4A/His (Invitrogen, Cerey-Pontoise, France) between EcoRI and XbaI sites. VavT205A mutation was obtained using the QuickChange mutagenesis kit (Stratagene) using specific primer. Truncated cDNA of vavL was generated by creating an EcoRI Differential Bcr-Abl-induced cell motility T Daubon et al site at codon 171 of the cDNA of wt Vav cloned in EF4A/His (Invitrogen) followed by digestion using EcoRI. Every cDNAs were subjected to sequence analysis to avoid the possibility of additional mutations. To obtain Vav-or mutant-Vav-expressing cells, Ba/F3p190 and Ba/F3p210 cells were co-transfected by electroporation with pEF4A vector containing the cDNAs of the different forms of Vav. After 2 days of transfection, selection was applied by adding use zeocin (0.04% w/v) for 3 weeks. Cloning of cell lines was made by selection in 96 wells of dilutions to 0.3 cell per well. Cells were then cultured in the presence of zeocin (0.04% w/v) and survived without IL-3 except Ba/F3VavL cells, which remained dependent on rm-IL-3 (10 ng ml À1 ). Affinity-binding assay, immunoprecipitations, SDS-PAGE and immunoblots Affinity-binding assay using Rhotekin-Rho-binding domain (RBD) or PAK-cdc42/Rac interacting and binding domain (PAK-CRIB) to determine the presence of activated RhoA or Rac1, immunoprecipitations using anti-Vav or anti-Abl, sodium dodecyl sulfate-PAGE (SDS-PAGE), western blots and immunorevelation were performed as previously described (Harnois et al., 2003) . CGP-571 was provided generously by E Buchdunger (Novartis).
Recombinant proteins
Recombinant proteins were prepared as glutathione S-transferase fusion proteins in Escherichia coli (BL21 strain), purified using glutathione-sepharose beads (GE Healthcare), eluted with glutathione and used as glutathione S-transferase (GST)-fusion proteins. The GST-PAK-CRIB domain and GST-RBD (C21) were obtained as pGEX-2T fusion genes (gift of JG Collard, Netherlands Cancer Institute, Amsterdam, NL) and produced as described (Sander et al., 1998) .
Transwell experiments
Cell migration was assayed using inserts containing 3D matrigel coated on 8 mm porous filters (BD BioCoat Growth Factor Reduced MATRIGEL Invasion Chamber). A total of 2.5 Â 10 4 cells in 1 ml of RPMI1640 culture medium supplemented with 10% fetal calf serum (FCS) were added to the inserts, while 750 ml of the same culture medium were added in the wells. Cells were incubated for 48 h at 37 1C in a CO 2 incubator. Cells were counted using an ocular micrometer every 24 h. We measured in parallel the proliferation rate during the transwell experiment. Data presented are the result of total migrated cell counting divided by the proliferation rate at the indicated times. Data are presented as relative migration using wild-type Ba/F3 cells as control and represent mean ± s.d. of five or six experiments.
ShRNA transfection and characterization
Sequences of vav-specific and control shRNA were contained in pGeneClip hMGFP vector (control shRNA-GGAATCT CATTCGATGCATAC-; shRNA1-AGCCATATGTTCCTT CTGATT-and shRNA2-TGCCCAGAACAAAGGAATCAT-) (SuperArray Bioscience Corporation, Frederick, MD, USA). Plasmids containing control shRNA and vav-specific shRNA were produced in E. coli. Plasmid maxipreparation were performed using Qiafilter MaxiPrep (Qiagen, Courtaboeuf, France) and DNA concentrations were measured by spectrophotometry. A total of 2 mg of each shRNA was transfected in Ba/F3p190 or Ba/F3p210 cells using a nucleofector device with cell line Nucleofector kit V (Amaxa biosystems, Ko¨ln, Germany). Cells were incubated at 37 1C with 5% CO 2 during 24 h, counted and seeded on transwell inserts as described above. A part of the cells was cultured for additional 24 h, counted and lysed as described above for western blot and GST-PAK-CD pull-down analysis. In parallel, FACS analysis of GFP and Vav content of transfected cells was performed on a FACScanto II (Becton-Dickinson).
Time-lapse recordings A total of 10 5 cells were collected, centrifuged and included in 2 mg ml À1 liquid Matrigel (Becton Dickinson) or 2 mg ml
À1
Collagen (Becton Dickinson) diluted in RPMI1640 supplemented with 10% FCS at 4 1C. The mixture was then cast into a 1 cm diameter 2 mm high Teflon ring on a 30 mm coverslip. Cells on the coverslip were then incubated for 6 h at 37 1C in a CO 2 incubator. For C3 exoenzyme experiment, cells were preincubated with Ia-C3 (5 mg ml
) and Ib (8 mg ml À1 ) for 6 h at 37 1C according to Marvaud et al. (2002) before inclusion into Matrigel.
Cell imaging with differential interference contrast microscopy was performed by means of an Olympus FV1000 laser scanning confocal station, equipped with a 30 mW multiline argon laser. The confocal unit was connected to an inverted microscope (Olympus IX81, Tokyo, Japan). Maximal resolution was obtained with Olympus Uplan apo Â 60 water, 1.3 numerical aperture objective lens. Images were recorded each second for 10 min. Movies presented in Supplementary section were cut to 4 or 5 min and are 12-fold accelerated (12 frames per s).
Statistics
Results are expressed as mean±s.e.m. of n observations. Sets of data were compared with a Student's t-test. Differences were considered statistically significant when Po0.05 (ns, not significant difference; **Po0.01; ***Po0.001). All statistical tests were performed using GraphPad Prism version 4.0 for Windows (Graphpad Software).
